1. MAPK/ERK Pathway
    Autophagy
  2. p38 MAPK
    Autophagy
  3. SB 239063

SB 239063 

Cat. No.: HY-11068 Purity: 99.53%
Handling Instructions

SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD.

For research use only. We do not sell to patients.

SB 239063 Chemical Structure

SB 239063 Chemical Structure

CAS No. : 193551-21-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 145 In-stock
Estimated Time of Arrival: December 31
5 mg USD 132 In-stock
Estimated Time of Arrival: December 31
10 mg USD 216 In-stock
Estimated Time of Arrival: December 31
50 mg USD 816 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 16 publication(s) in Google Scholar

Top Publications Citing Use of Products

    SB 239063 purchased from MCE. Usage Cited in: Int Immunopharmacol. 2016 Sep;38:54-60.

    The protective role of p38 MAPK inhibition in II/R-induced ALI and regulation of AQP4 in rats. HE staining and Lung wet/dry weight ratio show obvious evidences of ALI and lung edema. Western blot and immunofluorescent staining confirm the increased expression levels of AQP4 and P-p38 MAPK protein in the lung tissues. Then, the p38 MAPK inhibitor is administrated intraperitoneally. Results show that p38 MAPK inhibition downregulates AQP4 expression in the lungs and protected lung from acute injur

    SB 239063 purchased from MCE. Usage Cited in: Front Pharmacol. 2017 Nov 14;8:808.

    Immunofluorescence staining of α-actinin and the cell surface area of cardiomyocytes in the indicated groups (n=5 samples and n=100+cells per group).

    SB 239063 purchased from MCE. Usage Cited in: China Biotechnology. 2017, 37(12): 40-48.

    The Western blot analysis of HOG1 and Phospho-HOG1.

    SB 239063 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Jun 28;37(1):128.

    MHCC-97H cells are transfected with control or supervillin-specific siRNA for 48 h, exposed to hypoxia for 16 h, and lysates are assayed for the relative amounts of GTP-loaded (activated) Rac1, Cdc42, and RhoA. Cells that have been transfected with control RNAi are treated with a PD0325901 or SB239063 before assaying for GTP-Rac1, Cdc42, and RhoA levels.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD[1][2].

    IC50 & Target

    IC50: 44 nM (Human p38α)[1]

    In Vitro

    SB 239063 (0.1–10 μM ; 29 hours, 47 hours) increases apoptosis of eosinophils in a dose-related in the presence of 10 pM IL-5 at every time point from 21 hours onwards[1].
    SB 239063 potently inhibits IL-1 and TNF- a production in LPS-stimulated human peripheral blood monocytes with IC50 values of 120 nM and 350 nM, respectively[1].

    Apoptosis Analysis[1]

    Cell Line: Eosinophils (guinea pig BALs)
    Concentration: 0.1μM, 1μM, 10μM
    Incubation Time: 29 hours, 47 hours
    Result: Increased apoptosis of eosinophils in a dose-related in the presence of 10 pM IL-5 at every time point from 21 hours onwards.
    In Vivo

    SB 239063 (12 mg/kg; p.o.; 1 hour before and 4 hours after OA challenge; b.i.d. for 3 days) significantly inhibits the resultant antigen-induced airway eosinophilia[1].
    SB 239063 (12 mg/kg; p.o.) almost abolishes ovalbumin (OA)-induced airway eosinophilia (~ 93% inhibition) by inhalation[1].
    SB 239063 is a potent inhibitor of LPS-induced TNF-alpha production in the mouse peritoneal cavity with an EC50 of 5.8 mg/kg (2.8–10.3; 95% CL)[1].

    Animal Model: Male BALB/c mice (18–20 g)[1]
    Dosage: 12 mg/kg
    Administration: Oral administration; 1 h before and 4 h after OA challenge; bis in die for 3 days
    Result: Significantly inhibited the resultant antigen-induced airway eosinophilia.
    Molecular Weight

    368.40

    Formula

    C₂₀H₂₁FN₄O₂

    CAS No.

    193551-21-2

    SMILES

    COC1=NC=CC(C2=C(N=CN2[[email protected]]3CC[[email protected]](O)CC3)C4=CC=C(F)C=C4)=N1

    Shipping

    Room temperature in continental US; may vary elsewhere

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 33.33 mg/mL (90.47 mM; Need ultrasonic)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7144 mL 13.5722 mL 27.1444 mL
    5 mM 0.5429 mL 2.7144 mL 5.4289 mL
    10 mM 0.2714 mL 1.3572 mL 2.7144 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (6.79 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (6.79 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    SB 239063
    Cat. No.:
    HY-11068
    Quantity: